SCHEMBL5312758

SCHEMBL5312758

O=C(CN1CCN(S(=O)(=O)c2ccc(C(=O)O)cc2)CC1)Nc1ccc(Oc2ccccc2)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 2/20 0.70
CHRNB2 P17787 5/20 0.68
CHRNB4 P30926 5/20 0.68
CHRNA3 P32297 5/20 0.68
CHRNA4 P43681 5/20 0.68
HTT P42858 2/20 0.63
LMNA P02545 4/20 0.62
SMN1; SMN2 Q16637 3/20 0.62
GAA P10253 3/20 0.62
ALDH1A1 P00352 3/20 0.62
POLB P06746 1/20 0.62
MAPT P10636 2/20 0.61
GLA P06280 2/20 0.60
MEN1 O00255 1/20 0.60
KMT2A Q03164 1/20 0.60
CYP1A2 P05177 1/20 0.60
CYP3A4 P08684 1/20 0.60
CYP2C9 P11712 1/20 0.60
TSHR P16473 1/20 0.60
CYP2C19 P33261 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5309852 0.96 LTA4H (0.71) LTA4HCHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL5312332 0.89 CHRNB4 (0.64) LTA4HCHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL5317908 0.83 LTA4H (1.00) LTA4HLMNASMN1; SMN2GAAALDH1A1
SCHEMBL5315377 0.83 LTA4H (0.76) LTA4HLMNASMN1; SMN2GAAALDH1A1
SCHEMBL5658691 0.82 LMNA (0.74) LTA4HCHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL5314942 0.81 LTA4H (0.73) LTA4HLMNASMN1; SMN2GAAALDH1A1
SCHEMBL5312794 0.80 LTA4H (1.00) LTA4HLMNASMN1; SMN2GAAALDH1A1
SCHEMBL5471639 0.80 LTA4H (0.81) LTA4HLMNASMN1; SMN2GAAALDH1A1
SCHEMBL5312685 0.79 LTA4H (0.76) LTA4HLMNASMN1; SMN2GAAALDH1A1
SCHEMBL5659106 0.79 LTA4H (0.76) LTA4HLMNASMN1; SMN2GAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007079003-A2 AMIDE INHIBITORS OF LEUKOTRIENE A4 HYDROLASE BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2007-07-12 WO claimed
WO-2007079003-A2 AMIDE INHIBITORS OF LEUKOTRIENE A4 HYDROLASE BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2007-07-12 WO disclosed
US-20070155727-A1 Amide inhibitors of leukotriene A4 hydrolase SCHERING AKTIENGESSELLSCHAFT (DE) 2007-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070155727-A1 Amide inhibitors of leukotriene A4 hydrolase LTA4H, LTB4R, LTC4S LTA4H 1/4885CHRNB2 2083/4885CHRNB4 1080/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.